Key facts
- Vetmab Bio’s last known valuation is $9.2M (Aug 2022).
- It has raised $3.4M; the latest was Early Stage VC ($850K) in Apr 2025.
- Notable investors include Flybridge (New York), CONNECT (San Diego), XFactor Ventures, Ascendant Venture, Yuhan.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Vetmab Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Vetmab Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vetmab Bio
Developer of therapeutic drugs designed to bring safe and effective mAb therapies to treat animal diseases. The company focuses on developing life-improving drugs for crippling and hard-to-treat conditions in both dogs and cats, enabling veterinarians to treat pet animals effectively.
- Sector
- Consumer Products and Services (B2C)
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Employees
- 4
- Website
- vetmab.bio/
- Ownership
- Privately Held (backing)
Vetmab Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vetmab Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vetmab Bio in its N-PORT filings yet. We sweep new filings monthly.